MedTrace Logo

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

NCT06533059 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2026-03-09

No results posted yet for this study

Summary

The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.

Conditions

Interventions

DRUG

ALTA2618

Oral ALTA2618 tablets will be administered at protocol-defined dose

Sponsors & Collaborators

  • Alterome Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Study Medical Director · Alterome Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-22
Primary Completion
2026-12-29
Completion
2027-12-29
FDA Drug
Yes

Countries

  • United States
  • Australia
  • France
  • Japan
  • South Korea
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06533059 on ClinicalTrials.gov